| ABSTRACT Objective:To assess the effectiveness, safety, costs, and applicability by rapidly health technology assessment（HTA）on daptomycin to treat infective endocarditis, so as to provide currently available best evidence for decision makers of health policies in medication selection.Methods:Systematic review, Meta analysis, HTA and research of pharmacoeconomics regarding infective endocarditis treated by daptomycin were searched in the PubMed, the Cochrane Library, CNKI, WanFang Data, SinoMed. Literature were screened according to the inclusion and exclusion criteria, then data were extracted and quality of literature was assessed by two reviewer independently, and descriptive analysis was performed. Results: Three studies were finally included, encompassing one systems review, and two cost effective studies. The effectiveness and safety of daptomycin showed no significant difference with the control group (routine medication), economic studies have shown that more cost effectiveness than the control group. Conclusion:The evidence of this study showed that daptomycin was safe and effective in clinic after applying rapid health technology assessment. It was a tool could be used as a simple, fast, and easy way to provide a reference for the selection of medication in the hospital. |
